AIMS/HYPOTHESIS: Morbid obesity (BMI>40 kg/m(2)) affecting 0.5-5% of the adult population worldwide is a major risk factor for type 2 diabetes. We aimed to elucidate the genetic bases of diabetes associated with obesity (diabesity), and to analyse the impact of corpulence on the effects of diabetes susceptibility genes. METHODS: We genotyped known single nucleotide polymorphisms (SNPs) in the adiponectin-encoding adipocyte C1q and collagen-domain-containing (ACDC) gene (-11,391G>A, -11,377C>G, +45T>G and +276G>T), the peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala SNP and ACDC exon 3 variants in 703 French morbidly obese subjects (BMI 47.6+/-7.4 kg/m(2)), 808 non-obese subjects (BMI<30 kg/m(2)) and 493 obese subjects (30< or =BMI<40 kg/m(2)). RESULTS: Two 5'-ACDC SNPs -11,391G>A, -11,377C>G were associated with adiponectin levels (p=0.0003, p=0.008) and defined a "low-level" haplotype associated with decreased adiponectin levels (p=0.0002) and insulin sensitivity (p=0.01) and with a risk of type 2 diabetes that was twice as high (p=0.002). In contrast, the prevalence of the PPARG Pro12Ala was identical in diabetic and normoglycaemic morbidly obese subjects. The PPARG Pro12 allele only displayed a trend of association with type 2 diabetes in the non-obese group. ACDC exon 3 variants were associated with type 2 diabetes in the non-obese group only (odds ratio 7.85, p<0.0001). In contrast, the 5'-ACDC "low-level" haplotype was associated with type 2 diabetes in obese and morbidly obese subjects (odds ratio 1.73 and 1.92) but not in non-obese individuals. CONCLUSIONS/ INTERPRETATION: These data clarify the contribution of the 5'-ACDC SNPs to the risk of diabesity. Their interaction with corpulence suggests for the first time a different genetic profile of type 2 diabetes in morbidly obese patients compared with in less obese individuals.
AIMS/HYPOTHESIS: Morbid obesity (BMI>40 kg/m(2)) affecting 0.5-5% of the adult population worldwide is a major risk factor for type 2 diabetes. We aimed to elucidate the genetic bases of diabetes associated with obesity (diabesity), and to analyse the impact of corpulence on the effects of diabetes susceptibility genes. METHODS: We genotyped known single nucleotide polymorphisms (SNPs) in the adiponectin-encoding adipocyte C1q and collagen-domain-containing (ACDC) gene (-11,391G>A, -11,377C>G, +45T>G and +276G>T), the peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala SNP and ACDC exon 3 variants in 703 French morbidly obese subjects (BMI 47.6+/-7.4 kg/m(2)), 808 non-obese subjects (BMI<30 kg/m(2)) and 493 obese subjects (30< or =BMI<40 kg/m(2)). RESULTS: Two 5'-ACDC SNPs -11,391G>A, -11,377C>G were associated with adiponectin levels (p=0.0003, p=0.008) and defined a "low-level" haplotype associated with decreased adiponectin levels (p=0.0002) and insulin sensitivity (p=0.01) and with a risk of type 2 diabetes that was twice as high (p=0.002). In contrast, the prevalence of the PPARG Pro12Ala was identical in diabetic and normoglycaemic morbidly obese subjects. The PPARG Pro12 allele only displayed a trend of association with type 2 diabetes in the non-obese group. ACDC exon 3 variants were associated with type 2 diabetes in the non-obese group only (odds ratio 7.85, p<0.0001). In contrast, the 5'-ACDC "low-level" haplotype was associated with type 2 diabetes in obese and morbidly obese subjects (odds ratio 1.73 and 1.92) but not in non-obese individuals. CONCLUSIONS/ INTERPRETATION: These data clarify the contribution of the 5'-ACDC SNPs to the risk of diabesity. Their interaction with corpulence suggests for the first time a different genetic profile of type 2 diabetes in morbidly obese patients compared with in less obese individuals.
Authors: A G Comuzzie; T Funahashi; G Sonnenberg; L J Martin; H J Jacob; A E Black; D Maas; M Takahashi; S Kihara; S Tanaka; Y Matsuzawa; J Blangero; D Cohen; A Kissebah Journal: J Clin Endocrinol Metab Date: 2001-09 Impact factor: 5.958
Authors: Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer Journal: Lancet Date: 2003-01-18 Impact factor: 79.321
Authors: Claudia Menzaghi; Tonino Ercolino; Rosa Di Paola; Anders H Berg; James H Warram; Philipp E Scherer; Vincenzo Trischitta; Alessandro Doria Journal: Diabetes Date: 2002-07 Impact factor: 9.461
Authors: L Y Han; Q H Wu; M L Jiao; Y H Hao; L B Liang; L J Gao; D G Legge; H Quan; M M Zhao; N Ning; Z Kang; H Sun Journal: Diabetologia Date: 2011-06-03 Impact factor: 10.122
Authors: Sarah S Cohen; Marilie D Gammon; Kari E North; Robert C Millikan; Ethan M Lange; Scott M Williams; Wei Zheng; Qiuyin Cai; Jirong Long; Jeffrey R Smith; Lisa B Signorello; William J Blot; Charles E Matthews Journal: Obesity (Silver Spring) Date: 2011-01-27 Impact factor: 5.002
Authors: Ying Wu; Yun Li; Ethan M Lange; Damien C Croteau-Chonka; Christopher W Kuzawa; Thomas W McDade; Li Qin; Ghenadie Curocichin; Judith B Borja; Leslie A Lange; Linda S Adair; Karen L Mohlke Journal: Hum Mol Genet Date: 2010-09-27 Impact factor: 6.150
Authors: K J Mather; C A Christophi; K A Jablonski; W C Knowler; R B Goldberg; S E Kahn; T Spector; Z Dastani; D Waterworth; J B Richards; T Funahashi; F X Pi-Sunyer; T I Pollin; J C Florez; P W Franks Journal: Diabet Med Date: 2012-12 Impact factor: 4.359
Authors: Daruneewan Warodomwichit; Jian Shen; Donna K Arnett; Michael Y Tsai; Edmond K Kabagambe; James M Peacock; James E Hixson; Robert J Straka; Michael A Province; Ping An; Chao-Qiang Lai; Laurence D Parnell; Ingrid B Borecki; Jose M Ordovas Journal: Obesity (Silver Spring) Date: 2008-12-18 Impact factor: 5.002
Authors: G William Wong; Sarah A Krawczyk; Claire Kitidis-Mitrokostas; Tracy Revett; Ruth Gimeno; Harvey F Lodish Journal: Biochem J Date: 2008-12-01 Impact factor: 3.857